Neuromed Pharmaceuticals and Merck Collaborate for Novel Pain Drugs
Business Review Editor
Abstract
Neuromed and Merck & Co. entered into a research collaboration and worldwide licensing agreement to develop and commercialize novel compounds to treat chronic pain including the Neuromed’s Phase II compound, NMED-160.
Full Text: pdf
Add comment

This work is licensed under a Creative Commons Attribution 3.0 License.